Pacira Pharmaceuticals Inc (PCRX)

NASDAQ
Currency in USD
21.82
-0.25(-1.11%)
Real-time Data
PCRX Scorecard
Full Analysis
Management has been aggressively buying back shares
Fair Value
Day's Range
21.5022.16
52 wk Range
11.1634.01
Key Statistics
Edit
Prev. Close
22.06
Open
22.05
Day's Range
21.5-22.16
52 wk Range
11.16-34.01
Volume
21.16K
Average Volume (3m)
705.14K
1-Year Change
-30.28%
Book Value / Share
16.25
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PCRX Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
20.43
Downside
-6.38%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year
Show more

Pacira Pharmaceuticals Inc Company Profile

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

Employees
712

Pacira Pharmaceuticals Inc SWOT Analysis


Legal Hurdles
Pacira faces patent challenges and potential generic competition, threatening its market dominance with flagship product Exparel
Growth Amid Adversity
NOPAIN initiative and new partnerships offer hope for expansion, despite recent revenue miss and market pressures
Analyst Perspectives
Price targets range from $14 to $37, reflecting mixed outlook on Pacira's ability to navigate current challenges and capitalize on opportunities
Financial Resilience
Strong gross margins and free cash flow yield demonstrate Pacira's ability to maintain profitability in face of market uncertainties
Read full SWOT analysis

Pacira Pharmaceuticals Inc Earnings Call Summary for Q3/2024

  • EXPAREL sales rose to $132M in Q3; non-GAAP gross margin at 78%, adjusted EBITDA $54.7M
  • $163.2M non-cash charge for goodwill impairment due to EXPAREL patent lawsuit
  • 2024 revenue guidance reiterated at $680M-$705M; adjusted gross margins forecast 74%-76%
  • NOPAIN reimbursement policy expected to boost EXPAREL access from January 2025
  • Company focuses on non-opioid growth, preparing for accelerated expansion in 2025
Last Updated: 2024/11/07, 23:40
Read Full Transcript

Compare PCRX to Peers and Sector

Metrics to compare
PCRX
Peers
Sector
Relationship
P/E Ratio
−11.2x−4.3x−0.6x
PEG Ratio
0.000.120.00
Price/Book
1.4x1.0x2.6x
Price / LTM Sales
1.5x1.4x3.1x
Upside (Analyst Target)
−18.4%106.9%51.5%
Fair Value Upside
Unlock8.0%8.4%Unlock

Analyst Ratings

3 Buy
3 Hold
2 Sell
Ratings:
8 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 20.43

(-6.38% Downside)

Earnings

Latest Release
Nov 06, 2024
EPS / Forecast
0.79 / 0.7045
Revenue / Forecast
168.57M / 169.55M
EPS Revisions
Last 90 days

FAQ

What Is the Pacira (PCRX) Stock Price Today?

The Pacira stock price today is 21.82

What Stock Exchange Does Pacira Trade On?

Pacira is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Pacira?

The stock symbol for Pacira is "PCRX."

What Is the Pacira Market Cap?

As of today, Pacira market cap is 1.01B.

What is Pacira Earnings Per Share?

The Pacira EPS is -1.96.

What Is the Next Pacira Earnings Date?

Pacira will release its next earnings report on 26 Feb 2025.

From a Technical Analysis Perspective, Is PCRX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.